The Securities and Exchange Commission and Federal Trade Commission are investigating Abbott Laboratories’ baby-formula business, the company said.
The SEC’s enforcement division sent a subpoena to Abbott ABT, +0.62% in December requesting information about its powder infant-formula business and related public disclosures, the company said Friday in a securities filing.
This article was originally published by Marketwatch.com. Read the original article here.
